Erlotinib (Tarceva) for advanced non-small cell lung cancer

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2005年 / 47卷 / 1205期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Erlotinib (Tarceva) is the second oral epidermal growth factor receptor (EGFR) inhibitor to become available in the US for treatment of advanced refractory NSCLC. In clinical trials, erlotinib produced a response rate of only 8.9%, but increased median survival from 4.7 to 6.7 months. Patients who had never smoked and those with EGFR-positive tumors survived longer. Erlotinib is generally well tolerated; diarrhea and rash are the most common adverse effects.
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [21] Reviewing the safety of erlotinib in non-small cell lung cancer
    Reck, Martin
    Mok, Tony
    Wolf, Juergen
    Heigener, David
    Wu, Yi-long
    EXPERT OPINION ON DRUG SAFETY, 2011, 10 (01) : 147 - 157
  • [22] Erlotinib for the treatment of relapsed non-small cell lung cancer
    McLeod, C.
    Bagust, A.
    Boland, A.
    Hockenhull, J.
    Dundar, Y.
    Proudlove, C.
    Davis, H.
    Green, J.
    Macbeth, F.
    Stevenson, J.
    Walley, T.
    Dickson, R.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 41 - 47
  • [23] Experience with erlotinib in the treatment of non-small cell lung cancer
    Landi, Lorenza
    Cappuzzo, Federico
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (04) : 146 - 163
  • [24] Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
    Gatzemeier, Ulrich
    Pluzanska, Anna
    Szczesna, Aleksandra
    Kaukel, Eckhard
    Roubec, Jaromir
    De Rosa, Flavio
    Milanowski, Janusz
    Karnicka-Mlodkowski, Hanna
    Pesek, Milos
    Serwatowski, Piotr
    Ramlau, Rodryg
    Janaskova, Terezie
    Vansteenkiste, Johan
    Strausz, Janos
    Manikhas, Georgy Moiseevich
    Von Pawel, Joachim
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) : 1545 - 1552
  • [25] Phase II study of tarceva as third-line treatment in advanced non-small cell lung cancer
    de Castro, Javier
    Pallares, Cinta
    Gurpide, Alfonso
    Cobo, Manuel
    Paz-Ares, Luis
    Gonzalez-Larriba, Jose Luis
    Insa, Amelia
    Domine, Manuel
    Sanchez, Rocio
    Massuti, Bartomeu
    ANNALS OF ONCOLOGY, 2006, 17 : 236 - 236
  • [26] Initial experience with erlotinib in advanced non-small cell lung cancer in the Kingdom of Saudi Arabia
    Alolayan, A. A. M.
    Musaad, S.
    Bamefleh, H.
    Nounou, M.
    Jazieh, A. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Phase II Study of Erlotinib in Japanese Patients with Advanced Non-small Cell Lung Cancer
    Takahashi, Toshiaki
    Yamamoto, Nobuyuki
    Nukiwa, Toshihiro
    Mori, Kiyoshi
    Tsuboi, Masahiro
    Horai, Takeshi
    Masuda, Noriyuki
    Eguchi, Kenji
    Mitsudomi, Tetsuya
    Yokota, Soichiro
    Segawa, Yoshihiko
    Ichinose, Yukito
    Fukuoka, Masahiro
    Saijo, Nagahiro
    ANTICANCER RESEARCH, 2010, 30 (02) : 557 - 563
  • [28] Impacts of Treatment Lines and Initiation Timing of Erlotinib for Advanced Non-small Cell Lung Cancer
    Aoki, Takuya
    Igawa, Satoshi
    Furuya, Naoki
    Katagiri, Masato
    Hisata, Junichirou
    Tajiri, Sakurako
    Hayama, Naoki
    Mineshita, Masamichi
    Urano, Tetsuya
    Miyazawa, Teruomi
    Masuda, Noriyuki
    Abe, Tadashi
    ANTICANCER RESEARCH, 2012, 32 (02) : 601 - 608
  • [29] Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer
    Zhou, Songwen
    Ren, Shengxiang
    Yan, Lianghua
    Zhang, Ling
    Tang, Liang
    Zhang, Jie
    Zhou, Caicun
    RESPIROLOGY, 2009, 14 (05) : 709 - 715
  • [30] Phase I Study of Sunitinib and Erlotinib in Advanced Nonsquamous Non-small Cell Lung Cancer
    O'Mahar, Shannon E.
    Campbell, Toby C.
    Tien Hoang
    Seo, Songwon
    Kim, KyungMann
    Larson, Martha M.
    Marcotte, Sarah M.
    LoConte, Noelle K.
    Traynor, Anne M.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (05) : 951 - 953
12345